Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 321 across all filing types
Latest filing 2026-05-29 Director's Dealing
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 98% confidence The document is a Globe Newswire announcement titled "Notifications of Transactions by Persons Discharging Managerial Responsibilities" which specifically relates to the vesting and settlement of RSUs previously granted to a director. This is a standard insider transaction disclosure by company directors or senior management. This clearly falls under the "Director's Dealing" category.
2026-05-29 English
Íslensk þýðing á fyrri tilkynningu; Oculis tilkynnir um helstu niðurstöður úr fasa 3 DIAMOND rannsóknunum á OCS-01 við sjónhimnubjúg af völdum sykursýki
Regulatory Filings Classification · 85% confidence The document is a corporate press release (GlobeNewswire) announcing topline results from Phase 3 clinical trials and discussing forward-looking statements, trial endpoints, and upcoming analyst/fiscal events. It does not contain financial earnings data, formal financial statements, or detailed regulatory filings; nor is it an Annual/Interim Report, earnings release, proxy statement, or investor presentation. It does not fit any specific category except the catch-all Regulatory Filings (RNS) for miscellaneous announcements. Therefore, the correct classification is RNS.
2026-05-29 Icelandic
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
Regulatory Filings Classification · 20% confidence The document is a corporate press release announcing topline clinical trial results for a Phase 3 program and inviting investors to a conference call. It does not contain actual financial statements (so it is not an Interim or Annual Report), nor is it an earnings release focused on quarterly financial performance. It is not a regulatory form or proxy, nor does it fit capital markets, governance, or M&A categories. This type of general corporate announcement that does not neatly fit a specific category falls under the fallback 'Regulatory Filings' (RNS).
2026-05-29 English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 95% confidence The document is a notification of transactions by a person discharging managerial responsibilities (PDMR) relating to vesting and settlement of RSUs granted to a director. This matches an insider trading disclosure by company directors/executives. Therefore, it is classified as a Director’s Dealing report.
2026-05-28 Latin
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 90% confidence The document announces notifications of transactions by persons discharging managerial responsibilities (PDMRs), detailing vesting and settlement of RSUs and equity incentive awards granted to directors. This is a report of insider dealings by company directors. According to the filing definitions, this falls under Director's Dealing (Code: DIRS).
2026-05-15 English
Oculis birtir niðurstöður aðalfundar 2026 og tilkynnir um kjör Gregory D. Perry í stjórn félagsins
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a press release that discloses the official results of the 2026 Annual General Meeting, including vote outcomes on resolutions and the election of a new board member. This aligns with a Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-14 Icelandic

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.